Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - AUXILIUM PHARMACEUTICALS INC | a12-16718_2ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 31, 2012
Auxilium Pharmaceuticals, Inc.
(Exact Name of Registrant Specified in Charter)
|
Delaware (State or Other Jurisdiction of Incorporation) |
|
000-50855 (Commission File Number) |
|
23-3016883 (I.R.S. Employer Identification No.) |
|
40 Valley Stream Parkway |
|
|
|
Malvern, PA |
|
19355 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (484) 321-5900
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On July 31, 2012, Auxilium Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal quarter ended June 30, 2012. The full text of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
As previously announced, the Company will conduct a conference call today, Tuesday, July 31, 2012 at 10:00 a.m. ET to discuss results and highlights of the second quarter 2012. The presentation slides to be used during the call will be available on the “For Investors” section of the Company’s web site (http://www.auxilium.com) under the “Presentations” tab beginning at 7 a.m. ET on Tuesday, July 31, 2012. An audio feed of the conference call will be simultaneously web cast on the Company’s web site and will be available, along with the presentation slides, on the “For Investors” section of the Auxilium web site under the “Events” tab beginning at 10:00 a.m. ET on Tuesday, July 31, 2012, and will remain available for future review until August 31, 2012.
The information contained in, or that can be accessed through the Company’s web site, is not a part of this filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
The following press release is furnished as an exhibit to this Current Report on Form 8-K pursuant to Item 2.02 and shall not be deemed to be “filed”:
99.1 Press Release dated July 31, 2012 issued by Auxilium Pharmaceuticals, Inc.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
AUXILIUM PHARMACEUTICALS, INC. | |
|
|
| |
|
|
| |
|
Date: July 31, 2012 |
By: |
/s/ James E. Fickenscher |
|
|
|
|
|
|
|
James E. Fickenscher |
|
|
|
Chief Financial Officer |